Monoclonal antibody against human midkine
A monoclonal antibody, which recognizes at least two amino acids among amino acids located at position 69, position 79, position 81 and position 102 of human midkine, has been found to have excellent reactivity with and excellent neutralizing activity against human midkine. Moreover, the activity of suppressing the proliferation of tumor has been observed in the antibody having excellent neutralizing activity. The use of the antibody of the present invention makes it possible to treat cancer effectively and to detect or purify midkine efficiently.
1. A monoclonal antibody comprising
a light chain variable region including complementarity-determining regions comprising amino acid sequences defined by SEQ ID NOs: 21 to 23, and
a heavy chain variable region including complementarity-determining regions comprising amino acid sequences defined by SEQ ID NOs: 24 to 26.
2. The monoclonal antibody according to claim 1 , comprising
a light chain variable region including the amino acid sequence defined by SEQ ID NO: 27, and
a heavy chain variable region including the amino acid sequence defined by SEQ ID NO: 28.
3. A composition comprising the monoclonal antibody according to claim 1 as an active principle and a pharmaceutically acceptable carrier.
4. A method for treating a cancer in which the cancer cells have an increased expression of midkine, comprising administering to a human with said cancer a therapeutically effective amount of the monoclonal antibody according to claim 1 , thereby suppressing proliferation of tumors.
5. The method according to claim 4 , wherein the cancer is a neuroblastoma.
6. The method according to claim 4 , wherein the cancer is selected from the group consisting of esophageal carcinoma, thyroid carcinoma, bladder cancer, stomach cancer, pancreatic cancer, liver cancer, pulmonary cancer, breast cancer, neuroblastoma, glioblastoma, uterine cancer, ovarian cancer, and Wilms tumor.